Pharmacokinetics and Pharmacogenetics of Dabigatran

Pharmacokinetics and Pharmacogenetics of Dabigatran

Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists. However, pharmacokinetics and pharmacogenetics of dabigatran are variable. This can affect both effectiveness and sa...

Full description

Bibliographic Details
Main Authors:	A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2021-03-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	dabigatran etexilate dabigatran pharmacokinetics effectiveness safety ces1 abcb1 ugt2b15
Online Access:	https://www.rpcardio.com/jour/article/view/2400

Similar Items

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
by: Liu Y, et al.
Published: (2021-04-01)

Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation
by: Sh P Abdullaev, et al.
Published: (2019-08-01)

Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects
by: A. I. Skripka, et al.
Published: (2020-01-01)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
by: Xin Li, et al.
Published: (2020-04-01)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
by: Bryan H. Simpson, et al.
Published: (2019-07-01)

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty
by: Sychev DA, et al.
Published: (2018-07-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

Cost/effectiveness model of dabigatran in the prevention of venous thromboembolism in major orthopedic surgery: Adaptation for Italy
by: Orietta Zaniolo, et al.
Published: (2010-06-01)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01)

New indications for dabigatran: A suggestion from a drug use evaluation study
by: Farzaneh Ashrafi, et al.
Published: (2017-01-01)

Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect
by: Zhi-Chun Gu, et al.
Published: (2018-05-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)
by: Uğur Önsel Türk, et al.
Published: (2016-05-01)

Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate
by: Allen R. Wolfe, MD, MPH, et al.
Published: (2017-06-01)

Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery
by: Orietta Zaniolo
Published: (2009-09-01)

Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines
by: Alesha J. Smith, et al.
Published: (2020-01-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
by: Rosencher Nadia, et al.
Published: (2012-06-01)

The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation
by: A. V. Fonyakin
Published: (2015-06-01)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
by: Bryan H. Simpson, et al.
Published: (2018-10-01)

Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study
by: Rajesh Malhotra, et al.
Published: (2017-03-01)

Dabigatran etexilate: a direct thrombin inhibitor
by: M. Dugnani
Published: (2013-05-01)

Dabigatran etexilate, a novel oral direct thrombin inhibitor, for preventing thromboembolic events after knee replacement arthroplasty
by: Moghtadaee M, et al.
Published: (2012-02-01)

Recovery of Visual Function after Administration of Dabigatran Etexilate
by: Carl-Ludwig Schönfeld, et al.
Published: (2014-08-01)

Periprocedural Direct Oral Anticoagulant Management: The RA-ACOD Prospective, Multicenter Real-World Registry
by: Raquel Ferrandis, et al.
Published: (2020-04-01)

Ex-vivo Ex-Vivo Absorption Study of a Novel Dabigatran Etexilate Loaded Nanostructured Lipid Carrier Using Non-Everted Intestinal Sac Model
by: haithem N Abed, et al.
Published: (2019-12-01)

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2
by: E. V. Shlyakhto, et al.
Published: (2020-12-01)

Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy
by: Francesco Mennini, et al.
Published: (2012-09-01)

Ethyl 3-[3-amino-4-methylamino-N-(pyridin-2-yl)benzamido]propanoate
by: Gao-Ju Wen, et al.
Published: (2017-02-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
by: D. A. Sychev, et al.
Published: (2015-09-01)

Dabigatran etexilate in the prevention of cardioembolic complications in patients with non-valvular atrial fibrillation
by: IS Yavelov
Published: (2014-12-01)

An Exploratory Association Analysis of <i>ABCB</i><sub>1</sub> rs1045642 and <i>ABCB</i><sub>1</sub> rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban
by: Adela-Nicoleta Roşian, et al.
Published: (2020-09-01)

The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy
by: Taki Galanis, MD, et al.
Published: (2014-12-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
by: Esme Ekizoğlu
Published: (2018-06-01)

The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis
by: S. P. Abdullaev, et al.
Published: (2020-11-01)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
by: Giannandrea D, et al.
Published: (2019-05-01)

Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation
by: Koji Miyamoto, et al.
Published: (2014-02-01)